Figure 1 | Site-selective reactions of benzene. a, When a benzene ring has a chemical group (R) attached, the carbon atoms in the ring are defined as being in the ortho-, meta-and parapositions, depending on their relationship to the point of attachment. If R is an electron-donating group, classical reactions of benzene rings attach electrophiles (E + , compounds that are attracted to electron-rich regions of molecules) to the ortho-and/or para-positions, which can lead to undesirable mixtures of isomeric products. b, In directed ortho-metalation reactions and C-H activation reactions, a 'directing' group (DG) guides metal atoms (M) only to the ortho-position; the broken line indicates the directing effect. The metal is then displaced by a different group to form a final product (not shown). For ortho-metalation, M is lithium or magnesium; for ortho-C-H activation, M is palladium, copper, rhodium, ruthenium or iridium. c, Yu and colleagues 2 have designed benzene-containing systems in which removable linker units bear groups that guide metal atoms to the meta-position. M is palladium. d, The first of their linkers attaches to benzene through an oxygen atom; the resulting compound is known as a benzyl ether. The second linker attaches through an amide bond (N-CO). Nitrile groups (CN) act as the directing groups in both cases. The carbon-hydrogen bond activated in the authors' reactions is shown in green. t-Bu is a tertiary butyl group, C(CH 3 ) 3 . reactions, presumably because the directing group blocks the approach of bulky alkenes. In Yu and colleagues' reactions, however, more space is available around the meta-position, allowing reactions with these large alkenes to occur.
Having demonstrated that their innovative reaction works with a reasonable range of substrates, the authors went on to solve the problem of how to remove the linkers 14 once meta-functionalization has occurred. This is necessary because molecules used as pharmaceuticals or materials do not have such linker groups in their structures. The researchers found that the benzyl ether can be removed by reacting it with hydrogen, whereas the other linker (an amide; Fig 1d) can be removed by treating it with a base in water. In the latter case, the cleaved linker survives the removal conditions, allowing it to be reclaimed and reused, further adding to the value of this approach for meta-functionalization. Yu and colleagues demonstrated the synthetic usefulness of their method by meta-functionalizing a derivative of the drug baclofen, opening up the possibility of using the technique to make analogues of other known drugs and so to generate new, potentially biologically active molecules.
Although the preliminary nature of these results prevents any definitive analysis, a comparison with Gaunt's meta-functionalization technique 11, 12 is appropriate and valuable. The huge size of Yu and colleagues' linkers is a current drawback, because it limits the practicality and scalability of the method compared with Gaunt's procedure -although this issue will undoubtedly be addressed by the researchers. On the other hand, Gaunt's method requires reagents (hypervalent iodine compounds) that need to be prepared in advance, whereas Yu and colleagues' process uses more easily available alkenes.
Such criticisms, however, should not detract from both groups' great achievements: the development of powerful methods for the meta-functionalization of electron-rich aromatic rings. These methods open up many opportunities for the synthesis of aromatic compounds, and perhaps also of heteroaromatic compounds -benzene-like compounds that incorporate nitrogen, oxygen and sulphur atoms in their rings. Yu and colleagues' chelation-driven approach to obtaining metaselective reactions will undoubtedly be eagerly pursued in the hope of developing other ways to selectively functionalize aromatic molecules. 
A false sense of non-self
A drug used for HIV treatment can alter the set of antigens that activates T cells of the immune system, thereby triggering life-threatening reactions against the body's own proteins. See Letter p.554
E L L I S L . R E I N H E R Z
T he drug abacavir can be an effective treatment for HIV but it is also associated with an autoimmune response in 5-10% of patients 1 . These hypersensitivity reactions, which include fever, rash and gastrointestinal problems, mandate immediate drug cessation to prevent the emergence of life-threatening symptoms. It has previously been reported 2,3 that abacavir hypersensitivity syndrome occurs in patients who express one particular major histocompatibility complex (MHC) class I protein, and genetic screening for this protein variant is an effective way to avoid this adverse drug reaction 4 . In an elegant study on page 554 of this issue, Illing et al. 5 reveal the molecular basis of this response, showing that abacavir alters the repertoire of antigens that activate the immune system.
T cells are immune cells that allow the body to distinguish abnormal or foreign cells from normal cells. The ability of T cells to discriminate between 'self ' and 'non-self ' is endowed by surface-bound T-cell receptors (TCRs) 6 . In any mammal, there are millions to billions of T cells, each with a slightly different (Fig. 1a) . T cells are able to detect a variant peptide even if just a few copies are present among the hundreds of thousands of normal self peptides that are displayed by the cell-surface MHC receptors 8 . In humans, the MHC molecules are called HLA proteins, and different people express versions encoded by different gene variants (alleles). In general, peptides associate with HLA molecules by inserting parts of their amino-acid residues into a set of six binding pockets (termed A-F) in the HLA 9 . The structure of these pockets is highly allele-specific, thereby dictating peptide-binding preferences for each HLA molecule. Illing et al. show that abacavir binds directly to the F pocket of one of these proteins, HLA-B*57:01, but that the drug does not bind to the closely related molecule HLA-B*57:03, which is not linked to abacavir hypersensitivity.
Illing and colleagues also reveal that the binding of abacavir to HLA-B*57:01 alters the F pocket's binding preference for side chains of the amino acids tryptophan or phenylalanine, so as to include those of the amino acids isoleucine and leucine. By determining the amino-acid sequences of almost 2,500 HLA-B*57:01-bound peptides, the researchers demonstrated an enormous shift in peptide presentation: 20-25% of the peptides bound by the HLA molecule following drug treatment differed from those that bound beforehand. The authors observed no such drug-induced change in the peptides that bound to HLA-B*57:03.
These data imply that HLA-B*57:01 and abacavir form a complex before the HLA molecules are loaded with peptides inside the cell, thereby altering the pool of self peptides that are bound to the HLA and displayed on the cell surface for CD8 + T-cell recognition. This shift in the specific HLA-associated cellsurface-peptide display leads to the activation of different CD8 + T cells (Fig. 1b) . However, the authors detected no obvious skewing towards a single CD8 + T-cell population, or clone, being activated by the altered range of peptides. Instead, they observed responses by many different CD8 + T cells (polyclonality). This is in keeping with a previous study 10 that revealed broad-scale activation of CD8 + T cells as the cellular basis of abacavir hypersensitivity reactions.
To examine the structural cause of the change in bound peptides, the authors refolded the HLA-B*57:01 protein in the presence of abacavir and a self peptide that binds to the HLA molecule only after drug treatment. They then compared the X-ray crystallographic structure of the resulting HLA-B*57:01-self-peptide complex with that of a different HLA-B*57:01-self-peptide complex that forms in the absence of abacavir. The researchers found that part of the drug, the cyclopropyl moiety, protrudes into the HLA molecule's F pocket, reducing the pocket's size, which accounts for its preferred binding of smaller amino acids following drug exposure. The structures also revealed that abacavir binds to the two amino-acid residues that are unique to the HLA-B*57:01 molecule, thereby explaining the drug's allele specificity.
This shift in the bound-peptide repertoire is a plausible explanation for drug-induced hypersensitivity. As T cells develop in the thymus, TCRs are randomly generated by a process of gene rearrangement. A mechanism referred to as negative selection 11 ensures that any developing T cell expressing a receptor that strongly recognizes self peptides bound to self-MHC molecules is destroyed, whereas T cells that lack self-reactivity but that have the potential to recognize foreign antigens survive.
Some self peptides are never encountered during T-cell development but can be exposed during pathological conditions 10 -when this occurs, a situation of 'mistaken identity' can arise, in which the self peptides are perceived as foreign by the immune system. For example, the eye is an immune privileged site, such that some ocular proteins are hidden from the immune system. However, if these proteins are released into the body -as occurs following a traumatic eye injury -T cells are activated, leading to inflammation in both the injured and uninjured eyes. This condition, referred to as sympathetic ophthalmia, can result in catastrophic blindness. It seems that the autoimmune response associated with abacavir treatment stems from a similar effect -the exposure of self peptides attached to HLA-B*57:01 that are 5 show that the anti-HIV drug abacavir binds to a specific HLA molecule and alters its peptide-binding characteristics, causing the HLA molecule to load and display a new range of peptides on the cell surface. Because this repertoire includes self peptides that were not displayed during T-cell development, the immune system contains some T cells that can recognize these antigens and launch an immune attack against the cell. not normally associated with this molecule leads T cells to perceive these self peptides as foreign.
This false sense of non-self is not restricted to abacavir. Illing et al. show that the anticonvulsive drug carbamazepine, which is associated with hypersensitivity responses in patients with the HLA-B*15:02 allele, also binds to that HLA molecule and alters its set of associated peptides. The awareness engendered by this study is likely to result in many more examples of known drug-HLA associations 12 being linked to similar autoimmune mechanisms. If so, it may become desirable to screen patients for their HLA alleles before choosing drugs for treatment. By extension, it is possible that organ-specific drug-metabolism processes might limit the altered HLA-peptide display to specific cell types, and thus limit the resulting immune reaction to certain organs, such as the liver, kidneys or bone marrow.
Finally, it is worth considering that environmental toxins and other chemicals could also interact with HLA molecules. The genes that encode HLA are extremely variable -at the last count, there were 4,269 different HLA (-A,-B and -C) variants referred to as MHC class I molecules 13 . This diversity is believed to have evolved owing to the selection pressures imposed by infectious pathogens 14 , but it also seems to afford ample opportunity for HLA interactions with drugs and other molecules. Similar drug interactions undoubtedly exist for the other class of HLA molecules (MHC class II, with -DR, -DP and -DQ types) that binds peptides recognized by CD4 + T cells. The field of pharmacogenetics is going to expand and, in so doing, redefine our understanding of the basis of many forms of autoimmunity. ■ 3 and Charrier et al. 4 detail how the SRGAP2 gene, which is found as a single copy in the genomes of most mammals, was duplicated three times during the evolution of human ancestors to give rise to four similar versions of the gene, named A-D. b, Charrier et al. demonstrate that the 'ancestral' version, SRGAP2A, stimulates the maturation of dendritic spines (protuberances) on the surfaces of neurons, whereas SRGAP2C promotes an increased number of immature spines in humans. This development might have contributed to the evolution of human cognitive abilities.
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and are more prone to sequence variations among humans, than are the A and C copies. They therefore suggest that SRGAP2C might have played a major part in the emergence of the Homo lineage 2 million to 3 million years ago, when human brain specializations (such as those leading to the development of language, social cognition and problem solving) were probably evolving.
*This News & Views article was published online on 20 June 2012.
